Abstract
Purpose
Hesperidin holds potential in treating age-related macular degeneration, cataract and diabetic retinopathy. The aim of this study, constituting the first step towards efficient ocular delivery of hesperidin, was to determine its physicochemical properties and in vitro ocular tissue permeability.
Methods
pH dependent aqueous solubility and stability were investigated following standard protocols. Permeability of hesperidin across excised rabbit cornea, sclera, and sclera plus retinal pigmented epithelium (RPE) was determined using a side-bi-side diffusion apparatus.
Results
Hesperidin demonstrated poor, pH independent, aqueous solubility. Solubility improved dramatically in the presence of 2-hydroxypropyl-beta-cyclodextrin (HP-β-CD) and the results supported 1:1 complex formation. Solutions were stable in the pH and temperature (25, 40°C) conditions tested, except for samples stored at pH 9. Transcorneal permeability in the apical-basal and basal-apical directions was 1.11 ± 0.86 × 10−6 and 1.16 ± 0.05 × 10−6 cm/s, respectively. The scleral tissue was more permeable (10.2 ± 2.1 × 10−6 cm/s). However, permeability across sclera/choroid/RPE in the sclera to retina and retina to sclera direction was 0.82 ± 0.69 × 10−6, 1.52 ± 0.78 × 10−6 cm/s, respectively, demonstrating the barrier properties of the RPE.
Conclusion
Our results suggest that stable ophthalmic solutions of hesperidin can be prepared and that hesperidin can efficiently permeate across the corneal tissue. Further investigation into its penetration into the back-of-the eye ocular tissues is warranted.
Similar content being viewed by others
REFERENCES
A. Ryskulova, K. Turczyn, D. M. Makuc, M. F. Cotch, R. J. Klein, and R. Janiszewski. Self-reported age-related eye diseases and visual impairment in the United States: results of the 2002 national health interview survey. Am. J. Public Health. 98:454–461 (2008) doi:10.2105/AJPH.2006.098202.
J. L. Wilkinson-Berka. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des. 10:3331–3348 (2004) doi:10.2174/1381612043383142.
X. R. Chiou GC. Effects of some natural flavonoids on retinal function recovery after ischemic insult in the rat. J. Ocular. Pharmacol. Therap. 20:107–113 (2004) doi:10.1089/108076804773710777.
A. Garg, S. Garg, L. J. Zaneveld, and A. K. Singla. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother. Res. 15:655–669 (2001) doi:10.1002/ptr.1074.
J. M. Beiler, and G. J. Martin. Inhibition of hyaluronidase action by derivatives of hesperidin. J. Biol. Chem. 174:31–34 (1948).
J. Zhang, R. A. Stanley, L. D. Melton, and M. A. Skinner. Inhibition of lipid oxidation by phenolic antioxidants in relation to their physicochemical properties. Pharmacologyonline. 1:180–189 (2007).
A. Hirata, Y. Murakami, M. Shoji, Y. Kadoma, and S. Fujisawa. Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res. 25:3367–3374 (2005).
S. P. Ayalasomayajula, A. C. Amrite, and U. B. Kompella. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur. J. Pharmacol. 498:275–278 (2004) doi:10.1016/j.ejphar.2004.07.046.
E. M. Galati, M. T. Monforte, S. Kirjavainen, A. M. Forestieri, A. Trovato, and M. M. Tripodo. Biological effects of hesperidin, a citrus flavonoid. (Note I): antiinflammatory and analgesic activity. Farmaco. 40:709–712 (1994).
M. T. Monforte, A. Trovato, S. Kirjavainen, A. M. Forestieri, E. M. Galati, and R. B. Lo Curto. Biological effects of hesperidin, a citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco. 50:595–599 (1995).
E. M. Galati, A. Trovato, S. Kirjavainen, A. M. Forestieri, A. Rossitto, and M. T. Monforte. Biological effects of hesperidin, a citrus flavonoid. (Note III): antihypertensive and diuretic activity in rat. Farmaco. 51:219–221 (1996).
T. Tanaka, H. Makita, M. Ohnishi, H. Mori, K. Satoh, A. Hara, T. Sumida, K. Fukutani, T. Tanaka, and H. Ogawa. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res. 57:246–252 (1997).
T. Tanaka, H. Makita, K. Kawabata, H. Mori, M. Kakumoto, K. Satoh, A. Hara, T. Sumida, T. Tanaka, and H. Ogawa. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis. 18:957–965 (1997) doi:10.1093/carcin/18.5.957.
B. Ameer, R. A. Weintraub, J. V. Johnson, R. A. Yost, and R. L. Rouseff. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin. Pharmacol. Ther. 60:34–40 (1996) doi:10.1016/S0009-9236(96)90164-2.
A. Gil-Izquierdo, M. I. Gil, F. A. Tomas-Barberan, and F. Ferreres. Influence of industrial processing on orange juice flavanone solubility and transformation to chalcones under gastrointestinal conditions. J. Agric. Food Chem. 51:3024–3028 (2003) doi:10.1021/jf020986r.
T. H. Tsai, and M. C. Liu. Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 806:161–166 (2004) doi:10.1016/j.jchromb.2004.03.047.
Y. Mitsunaga, H. Takanaga, H. Matsuo, M. Naito, T. Tsuruo, H. Ohtani, and Y. Sawada. Effect of bioflavonoids on vincristine transport across blood–brain barrier. Eur. J. Pharmacol. 395:193–201 (2000) doi:10.1016/S0014-2999(00)00180-1.
M. Ofer, S. Wolffram, A. Koggel, H. Spahn-Langguth, and P. Langguth. Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur. J. Pharm. Sci. 25:263–271 (2005).
V. M. Breinholt, E. A. Offord, C. Brouwer, S. E. Nielsen, K. Brosen, and T. Friedberg. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem. Toxicol. 40:609–616 (2002) doi:10.1016/S0278-6915(01)00125-9.
S. Kobayashi, S. Tanabe, M. Sugiyama, and Y. Konishi. Transepithelial transport of hesperetin and hesperidin in intestinal Caco-2 cell monolayers. Biochim. Biophys. Acta. 1778:33–41 (2008) doi:10.1016/j.bbamem.2007.08.020.
H. Serra, T. Mendes, M. R. Bronze, and A. L. Simplicio. Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg. Med. Chem. 16:4009–4018 (2008).
C. Manach, C. Morand, A. Gil-Izquierdo, C. Bouteloup-Demange, and C. Remesy. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur. J. Clin. Nutr. 57:235–242 (2003) doi:10.1038/sj.ejcn.1601547.
A. K. Mitra, S. Macha, and P. M. Hughes. Ophthalmic Drug Delivery Systems. Marcel Dekker, New York, 2003.
M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248–254 (1976) doi:10.1016/0003-2697(76)90527-3.
N. M. Holekamp, M. A. Thomas, and A. Pearson. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am. J. Ophthalmol. 139:421–428 (2005) doi:10.1016/j.ajo.2004.09.046.
T. Jansen, B. Xhonneux, J. Mesens, and M. Borgers. Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res. 7:459–468 (1990).
P. Saarinen-Savolainen, T. Jarvinen, K. Araki-Sasaki, H. Watanabe, and A. Urtti. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharm. Res. 15:1275–1280 (1998) doi:10.1023/A:1011956327987.
T. Loftssona, and T. Jarvinen. Cyclodextrins in ophthalmic drug delivery. Adv. Drug Deliv. Rev. 36:59–79 (1999) doi:10.1016/S0169-409X(98)00055-6.
S. Tommasini, M. L. Calabro, R. Stancanelli, P. Donato, C. Costa, S. Catania, V. Villari, P. Ficarra, and R. Ficarra. The inclusion complexes of hesperetin and its 7-rhamnoglucoside with (2-hydroxypropyl)-beta-cyclodextrin. J. Pharm. Biomed. Anal. 39:572–580 (2005) doi:10.1016/j.jpba.2005.05.009.
D. K. Wilcox. Extracellular release of acid hydrolases from cultured retinal pigmented epithelium. Invest. Ophthalmol. Vis. Sci. 28:76–82 (1987).
A. J. Adler. Selective presence of acid hydrolases in the interphotoreceptor matrix. Exp. Eye Res. 49:1067–1077 (1989) doi:10.1016/S0014-4835(89)80027-2.
E. Mannermaa, K. S. Vellonen, and A. Urtti. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev. 58:1136–1163 (2006) doi:10.1016/j.addr.2006.07.024.
W. S. Marshall, and S. D. Klyce. Cellular and paracellular pathway resistances in the “tight” Cl- -secreting epithelium of rabbit cornea. J. Membr. Biol. 73:275–282 (1983) doi:10.1007/BF01870542.
M. R. Prausnitz, and J. S. Noonan. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87:1479–1488 (1998) doi:10.1021/js9802594.
V. Kansara, Y. Hao, and A. K. Mitra. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. J. Ocul. Pharmacol. Ther. 23:321–334 (2007) doi:10.1089/jop.2006.0150.
S. Majumdar, K. Hippalgaonkar, and M. A. Repka. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int. J. Pharm. 348:175–178 (2008) doi:10.1016/j.ijpharm.2007.08.017.
S. Majumdar, Y. E. Nashed, K. Patel, R. Jain, M. Itahashi, D. M. Neumann, J. M. Hill, and A. K. Mitra. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J. Ocul. Pharmacol. Ther. 21:463–474 (2005) doi:10.1089/jop.2005.21.463.
ACKNOWLEDGEMENT
This project was supported by NIH grant numbers P20RR021929, from the National Center for Research Resources, and EY018426-01 from the National Eye Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Eye Institute, National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Majumdar, S., Srirangam, R. Solubility, Stability, Physicochemical Characteristics and In Vitro Ocular Tissue Permeability of Hesperidin: A Natural Bioflavonoid. Pharm Res 26, 1217–1225 (2009). https://doi.org/10.1007/s11095-008-9729-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9729-6